Gismo Therapeutics Inc. is a privately held biotech company incorporated in Delaware. The Company offers an opportunity for investors to participate in an area of research with the potential to introduce breakthrough therapeutics for the treatment of Alzheimer’s Disease (AD) and Parkinson’s Disease. Highlights of this opportunity include:

  • New first-in-class drugs that address AD and PD
  • An experienced leadership team with a solid track record of drug development
  • Large and attractive market for novel oral AD and PD therapeutics
  • Multiple liquidity exits possible including upon identification of a Development Candidate, IND filing and positive results in human clinical studies


Worldwide sales of drugs to treat Alzheimer’s Disease was $4.3 billion in 2018. The AD drug market is forecast to be more than $13 Billion by 2023. Industry analysts predict a single new and truly effective AD drug could capture annual sales of over $10 billion. The annual market size for Parkinson’s Disease was about $4.0 Billion in 2016 and is expected to reach 5.69 by year 2022. Delaying disease progression is the greatest unmet need in the treatment of PD. GISMO Inc. believes that its rationally designed drugs are unique and there are no direct competitors.


For corporate partnership or investment opportunities, please contact:
Dr. Paul Gregor, CEO
Tel. 347-233-2037